Q-Linea
ISIN: SE0011527845 | Ticker: QLINEA | LEI: 549300BXVB4XRM8WSC73
Country: Sweden
Q-linea develops and delivers innovative solutions for the diagnosis of infectious diseases, with a keen focus on improving sepsis treatment while reducing antibiotic resistance
Q-linea is a company that develops innovative solutions for improved infectious disease diagnostics. The company focuses on developing instruments and consumables that benefit patients, healthcare providers and society. Q-linea develops and delivers solutions for healthcare providers, enabling them to diagnose and treat infectious diseases in the shortest possible time. The company’s leading product, ASTar®, is a fully automated instrument for antimicrobial susceptibility testing, which produces a sensitivity profile from a positive blood culture within ~six hours. This is 24 to 40 hours faster than current diagnostics.
2007
Served areaWorldwide
HeadquartersDag Hammarskjölds väg 52 A, 75237 Uppsala – Sweden
| Line item in (sek) | 01.01.2021 | 01.01.2022 | 01.01.2023 |
|---|---|---|---|
| Assets | 432,636,000.00 | 484,460,000.00 | 229,916,000.00 |
| Noncurrent Assets | 76,228,000.00 | 236,156,000.00 | 66,490,000.00 |
| Property Plant And Equipment | 21,821,000.00 | 27,669,000.00 | 36,362,000.00 |
| Goodwill | 4,889,000.00 | 4,889,000.00 | 4,889,000.00 |
| Other Intangible Assets | 587,000.00 | 390,000.00 | 235,000.00 |
| Current Assets | 356,407,000.00 | 248,303,000.00 | 163,426,000.00 |
| Inventories | 12,433,000.00 | 28,646,000.00 | 42,281,000.00 |
| Current Trade Receivables | 43,000.00 | 3,481,000.00 | 0.00 |
| Other Current Receivables | 35,198,000.00 | 48,440,000.00 | 45,798,000.00 |
| Cash and cash equivalents | 10,144,000.00 | 15,089,000.00 | 72,878,000.00 |
| Equity And Liabilities | 432,636,000.00 | 484,460,000.00 | 229,916,000.00 |
| Equity | 380,410,000.00 | 430,454,000.00 | 163,190,000.00 |
| Issued Capital | 1,367,000.00 | 1,477,000.00 | 1,477,000.00 |
| Retained Earnings | -571,190,000.00 | -804,858,000.00 | -1,073,255,000.00 |
| Other Reserves | -784,000.00 | -1,138,000.00 | -4,000.00 |
| Additional Paidin Capital | 951,017,000.00 | 1,234,972,000.00 | 1,234,972,000.00 |
| Equity Attributable To Owners Of Parent | 380,410,000.00 | 430,454,000.00 | 163,190,000.00 |
| Noncontrolling Interests | 0.00 | 0.00 | 0.00 |
| Liabilities | 52,226,000.00 | 54,006,000.00 | 66,726,000.00 |
| Noncurrent Liabilities | 15,727,000.00 | 13,235,000.00 | 14,813,000.00 |
| Noncurrent Financial Liabilities At Amortised Cost | 79,000.00 | 0.00 | 0.00 |
| Current Liabilities | 36,498,000.00 | 40,771,000.00 | 51,914,000.00 |
| Trade And Other Current Payables To Trade Suppliers | 8,068,000.00 | 8,103,000.00 | 21,555,000.00 |
| Current Accruals And Current Deferred Income Including Current Contract Liabilities | 18,241,000.00 | 14,456,000.00 | 12,629,000.00 |
| Current Tax Liabilities Current | 1,932,000.00 | 2,238,000.00 | 0.00 |
| Current Financial Liabilities At Amortised Cost | 252,000.00 | 79,000.00 | 0.00 |
| Other Current Liabilities | 3,463,000.00 | 10,969,000.00 | 11,613,000.00 |
| Line item in (sek) | 01.01.2021/ 01.01.2022 |
01.01.2022/ 01.01.2023 |
|---|---|---|
| Revenue | 9,335,000.00 | 12,788,000.00 |
| Other Income | 450,000.00 | 1,817,000.00 |
| Changes In Inventories Of Finished Goods And Work In Progress | -2,165,000.00 | 17,017,000.00 |
| Raw Materials And Consumables Used | 36,529,000.00 | 17,151,000.00 |
| Employee Benefits Expense | 110,512,000.00 | 145,639,000.00 |
| Depreciation And Amortisation Expense | 12,188,000.00 | 15,286,000.00 |
| Other Expense By Nature | 84,371,000.00 | 80,695,000.00 |
| Profit Loss From Operating Activities | -232,033,000.00 | -262,247,000.00 |
| Finance Income | 4,248,000.00 | 2,174,000.00 |
| Finance Costs | 3,650,000.00 | 8,621,000.00 |
| Profit Loss Before Tax | -231,435,000.00 | -268,694,000.00 |
| Income Tax Expense Continuing Operations | 0.00 | 0.00 |
| Profit (loss) | -231,435,000.00 | -268,694,000.00 |
| Profit Loss Attributable To Owners Of Parent | -231,435,000.00 | -268,694,000.00 |
| Profit Loss Attributable To Noncontrolling Interests | 0.00 | 0.00 |
| Line item in (sek) | 01.01.2021 | 01.01.2022 | 01.01.2023 |
|---|---|---|---|
| Profit (loss) | N/A | -231,435,000.00 | -268,694,000.00 |
| Adjustments For Reconcile Profit Loss | N/A | 10,399,000.00 | 15,261,000.00 |
| Adjustments For Decrease Increase In Inventories | N/A | -16,213,000.00 | -13,635,000.00 |
| Adjustments For Decrease Increase In Other Operating Receivables | N/A | -13,503,000.00 | 2,147,000.00 |
| Adjustments For Increase Decrease In Trade Account Payable | N/A | 36,000.00 | 13,451,000.00 |
| Adjustments For Increase Decrease In Other Operating Payables | N/A | 3,583,000.00 | -3,096,000.00 |
| Adjustments For Reconcile Profit Loss | N/A | 10,399,000.00 | 15,261,000.00 |
| Interest Paid Classified As Operating Activities | N/A | 2,098,000.00 | 8,825,000.00 |
| Interest Received Classified As Operating Activities | N/A | 3,735,000.00 | 2,599,000.00 |
| Cash Flows From Used In Operating Activities | N/A | -249,226,000.00 | -250,863,000.00 |
| Purchase Of Property Plant And Equipment Classified As Investing Activities | N/A | 12,135,000.00 | 17,249,000.00 |
| Cash Flows From Used In Investing Activities | N/A | -23,983,000.00 | 315,254,000.00 |
| Proceeds From Issuing Shares | N/A | 301,400,000.00 | 0.00 |
| Repayments Of Borrowings Classified As Financing Activities | N/A | 252,000.00 | 79,000.00 |
| Payments Of Lease Liabilities Classified As Financing Activities | N/A | 5,660,000.00 | 6,525,000.00 |
| Cash Flows From Used In Financing Activities | N/A | 278,153,000.00 | -6,604,000.00 |
| Increase (decrease) in cash and cash equivalents before effect of exchange rate changes | N/A | 4,945,000.00 | 57,787,000.00 |
| Effect Of Exchange Rate Changes On Cash And Cash Equivalents | N/A | 0.00 | 2,000.00 |
| Cash and cash equivalents | 10,144,000.00 | 15,089,000.00 | 72,878,000.00 |
Please note that some sums might not add up.
| Date | Trading entity / Person | Association | Trade type | Volume |
|---|---|---|---|---|
| 03.08.23 | Nexttobe AB | Other | Buy | SEK 69,397,836.00 |
| 21.07.23 | Christer Samuelsson | Other | Other | SEK 90,000.00 |
| 14.03.23 | Christer Samuelsson | Other | Buy | SEK 141,731.01 |
| 13.03.23 | Christer Samuelsson | Other | Buy | SEK 41,398.00 |
| 28.02.23 | Jonas Jarvius | Other | Buy | SEK 437,283.00 |
| 28.02.23 | CFO Akuten AB | Other | Buy | SEK 112,955.62 |
| 28.02.23 | Jonas Jarvius | Other | Buy | SEK 31,505.98 |
| 28.02.23 | Jonas Jarvius | Other | Buy | SEK 3,096.00 |
| 28.02.23 | Jonas Jarvius | Other | Buy | SEK 52.00 |
| 28.02.23 | Jonas Jarvius | Other | Buy | SEK 20.32 |
SE0011527845
LEI549300BXVB4XRM8WSC73
SectorHealth Care Equipment & Services
IndustryHealth Care Equipment & Supplies
Sub-IndustryKeep yourself informed with the most recent updates on FinancialReports, IPOs, product advancements, and other significant news.